注射用红花黄色素联合GP方案治疗中晚期乳腺癌的临床观察 点击下载
| 论文标题： | 注射用红花黄色素联合GP方案治疗中晚期乳腺癌的临床观察 |
| 英文标题： | |
| 中文摘要： | 目的：考察红花提取物联合GP（吉西他滨+顺铂）方案对中晚期乳腺癌的临床疗效及安全性。方法：98例中晚期乳腺癌患者按照随机数字表法分成研究组（A组）和对照组（B组），各49例。B组患者仅予以GP方案化疗，3周为1个疗程；A组患者采用GP方案化疗联合注射用红花黄色素100 mg静脉滴注，qd，2周为1个疗程。比较两组患者的临床疗效和治疗前后肿瘤坏死因子α（TNF-α）、血管内皮生长因子（VEGF）、基质金属蛋白酶2（MMP-2）、MMP-9等指标的变化差异，以及不良反应发生情况。结果：A组患者总有效率为83.7％，显著高于B组的63.3％，差异具有统计学意义（P＜0.05）。治疗后，两组患者TNF-α、VEGF、MMP-2及MMP-9等指标均较治疗前显著降低，差异具有统计学意义（P＜0.05），且A组降幅大于B组，差异具有统计学意义（P＜0.05）。两组患者除恶心呕吐发生率比较差异无统计学意义外，A组患者白细胞计数降低、贫血、脱发、食欲下降、肝功能异常、腹泻等不良反应发生率均显著低于B组，差异具有统计学意义（P＜0.05）。结论：对中晚期乳腺癌患者予以注射用红花黄色素联合GP化疗方案，可发挥红花提取物抗炎、促进血流灌注、抑制新生血管生成等功效，有效抑制病情发展、减轻化疗毒副反应。 |
| 英文摘要： | OBJECTIVE： To investigate the clinical efficacy and safety of Safflower yellow for injection combined with GP （gemcitabine+cisplatin） regimen for middle-advanced breast cancer. METHODS： 98 patients with middle-advanced breast cancer were randomly divided into study group （group A） and control group （group B）， with 49 cases in each group. Group B was only treated with GP regimen， and its treatment course lasted for 3 weeks. Group A was treated with GP regimen combined with intravenous dripping of Safflower yellow for injection 100 mg， qd， and the treatment course lasted for 2 weeks. Clinical efficacy， the variance of TNF-α， VEGF， MMP-2， MMP-9 and other indexes were compared between 2 groups before and after treatment， and the occurrence of ADR were compared. RESULTS： The total effective rate of group A was 83.7％， which was significantly higher than 63.3％ of group B， with statistical significance （P＜0.05）. After treatment， TNF-α， VEGF， MMP-2， MMP-9 and other indexes were significantly lower than before， with statistical significance （P＜0.05）； the decrease of group A was more significant than those of group B， with statistical significance （P＜0.05）. Except that there was no statistically significant difference in the incidence of nausea and vomiting between 2 groups， the incidence of ADR as white blood cell count decreasing， anemia， hair loss， loss of appetite， abnormal liver function and diarrhea in group A were significantly lower than those in group B， with statistical significance （P＜0.05）. CONCLUSIONS： For patients with middle-advanced breast cancer， to adopt Safflower yellow for injection combined with GP regimen can bring the effects of Safflower yellow for injection， such as anti-inflammation， improving blood infusion and inhibiting the generation of new vessel. And it can effectively inhibit the development of disease and alleviate toxic and side effects of chemotherapy. |
| 期刊： | 2016年第27卷第2期 |
| 作者： | 刘冉 |
| 英文作者： | LIU Ran |
| 关键字： | 注射用红花黄色素；GP化疗方案；中晚期乳腺癌；疗效 |
| KEYWORDS： | Safflower yellow for injection； GP chemotherapy regimen； Middle-advanced stage breast cancer； Curative efficacy |
| 总下载数： | 81次 |
| 本日下载数： | 2次 |
| 本月下载数： | 81次 |
| 文件大小： | 619.60Kb |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！